Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

Mounting evidence indicates that the presence of measurable (“minimal”) residual disease
(MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic …

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in
eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel …

PURPOSE The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit
patients with acute myeloid leukemia (AML) improves remission rates and survival …

Abstract Acute Myeloid Leukemia (AML) has a median age at diagnosis of 67 years. The
most common curative therapy remains an allogeneic hematopoietic stem cell …

Allogeneic stem cell transplantation with HLA-matched donors is increasingly used for older
patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It …

Allogeneic hematopoietic cell transplantation (alloHCT) in older patients requires the
weighing of risks and benefits for this potentially curative treatment while facing age-related …

Hematopoietic cell transplantation (HCT) is an effective treatment for many hematologic
malignancies, and its utilization continues to rise. However, due to the difficult logistics and …

Hematologic malignances are more common and often higher risk in older patients.
Allogeneic hematopoietic cell transplantation (alloHCT) best enables long-term disease …

Background Acute myeloid leukemia (AML) is both more common and with more biologically
aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the …